Manufacturing roundup: MilliporeSigma acquires bioreactor maker; Kite, Daiichi Sankyo change Yescarta agreement
MilliporeSigma, the US and Canadian life science business of Merck KGaA, has acquired Erbi Biosystems, a Massachusetts-based developer of a 2 ml micro-bioreactor technology dubbed the Breez platform.
The deal aims to strengthen MilliporeSigma’s position in the production of therapeutic proteins allowing for bioreactor processes from 2 ml to 2000 L, which can be key in “lab-scale process development,” and allows for more opportunities in developing cell therapies. Financial terms of the deal were not disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.